GLP-1Approved 2014

Dulaglutide

Last updated

GLP-1 receptor agonist. Once weekly.

Trulicity·Eli Lilly

Dulaglutide: lowest prices now

Other GLP-1 medicines at sellers we link to

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

No seller we link to sells dulaglutide; these are different medicines, compounded and not FDA-approved. Those sellers pay us if you buy, which never changes a price we show.

Catalog reviewed Nov 4, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

Data updated . What changed

Average A1c drop in its main trial

AWARD-1136 wks
−1.9 points (diabetesjournals.org/care/article/44/3/765/138650)

A1c shows average blood sugar over about three months. From one trial, not a head-to-head ranking.

What the FDA label says

  • Trulicity injectionGlucose control in adults and children 10+ with type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. FDA label (pi.lilly.com)
Information from FDA labels and published trials, not medical advice.

What to know about Dulaglutide

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

Sourced starting quote

from $389/28 days (lilly.com/lillydirect/trulicity)

28-day supply (lilly.com)

≈ $416.79 per 30 days at this quoted rate

Checked on lilly.com

Trulicity single-dose pens

LillyDirect (Eli Lilly) · self-pay, four weekly pens; published starting rate at each dose

Price conditions

self-pay, four weekly pens; published starting rate at each dose

The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. LillyDirect defines a month's supply as four single-dose pens, one a week, so a fill covers 28 days.

28-day supply

Quote at the cited trial dose

from $389/28 days (lilly.com/lillydirect/trulicity)

28-day supply (lilly.com)

≈ $416.79 per 30 days at this quoted rate

Checked on lilly.com

Trulicity single-dose pens · 4.5 mg

LillyDirect (Eli Lilly) · self-pay, four weekly pens; published starting rate at each dose

Price conditions

Published price at 4.5 mg

The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. LillyDirect defines a month's supply as four single-dose pens, one a week, so a fill covers 28 days.

The same starting rate is published for 0.75, 1.5, 3 and 4.5 mg. Taxes and additional fees may apply.

28-day supply

FDA-approved offers only in this summary. Starting and trial-dose quotes may cover different products. Every cash quote was checked on or after . Confirm eligibility, dose, fees, and supply length with the provider.

Mean weight change in the cited trial
≈−4.8% (diabetesjournals.org/care/article/44/3/765/138650) (-4.6 kg (~4.8% of the 95.4 kg baseline) at 36 wks · AWARD-11 · 4.5 mg weekly (Trulicity))

AWARD-11 · 4.5 mg weekly (Trulicity)

A1c reduction in the cited trial
−1.9 pp (diabetesjournals.org/care/article/44/3/765/138650) (-1.9% at 36 wks · AWARD-11 · HbA1c change in percentage points)

AWARD-11

Stopped treatment for adverse events
8.5% (pmc.ncbi.nlm.nih.gov/articles/PMC7896253) (8.5% vs 6.0% on the 1.5 mg comparator (no placebo arm) · AWARD-11 (4.5 mg, type 2 diabetes))

AWARD-11 (4.5 mg, type 2 diabetes)

FDA shortage report
No shortage reported

No matching shortage record was returned in the latest complete FDA check.

Route & frequency
Once weekly

Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.

Where to get it

Ways to get Dulaglutide

Compare sourced starting and maintenance-dose prices. Compounded products and membership fees are labeled separately.

5 current prices

  • View
    from $389/28 days (lilly.com/lillydirect/trulicity)

    ≈ $416.79 per 30 days

    Checked on lilly.com

    Top dose: same price at 4.5 mg

    Terms & source

    Advertised price: self-pay, four weekly pens; published starting rate at each dose

    28-day supply (lilly.com)

    ≈ $416.79 per 30 days at this quoted rate

    Top-dose terms: The same starting rate is published for 0.75, 1.5, 3 and 4.5 mg. Taxes and additional fees may apply.

    The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. LillyDirect defines a month's supply as four single-dose pens, one a week, so a fill covers 28 days.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Ingredient-level FDA shortage report:No shortage reportedOpen record
    Advertised price as read on its own page (lilly.com)
  • View
    ~$853 per 4 pens (singlecare.com/prescription/trulicity)

    ≈ $914.36 per 30 days

    Checked on singlecare.com

    Third-party report

    Top dose: No separate price on record

    Terms & source

    Advertised price: SingleCare coupon, lowest listed pharmacy price near ZIP 23666 for four 1.5 mg pens (four weekly doses, 28 days by the FDA label); free signup

    28-day supply (dailymed.nlm.nih.gov)

    ≈ $914.36 per 30 days at this quoted rate

    A discount card, not insurance. Trulicity has no generic. Prices vary by pharmacy and location.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Ingredient-level FDA shortage report:No shortage reportedOpen record
    Advertised price as read on its own page (singlecare.com)
  • R
    View
    ~$952 per 4 pens (rxsaver.com/drugs/trulicity)

    ≈ $1,019.97 per 30 days

    Checked on rxsaver.com

    Third-party report

    Top dose: No separate price on record

    Terms & source

    Advertised price: RxSaver coupon, lowest listed pharmacy price (Price Chopper) for one carton of four 0.75 mg/0.5 mL pens (four weekly doses, 28 days by the FDA label); the page names no ZIP; free coupon

    28-day supply (dailymed.nlm.nih.gov)

    ≈ $1,019.97 per 30 days at this quoted rate

    A discount card, not insurance. Trulicity has no generic. Prices vary by pharmacy and location.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Ingredient-level FDA shortage report:No shortage reportedOpen record
    Advertised price as read on its own page (rxsaver.com)
  • W
    Trulicity pens (WellRx coupon)

    WellRx

    View
    ~$968 per 4 pens (wellrx.com/prescriptions/trulicity/23666)

    ≈ $1,037.34 per 30 days

    Checked on wellrx.com

    Third-party report

    Top dose: No separate price on record

    Terms & source

    Advertised price: WellRx coupon, lowest listed pharmacy price (Food Lion Pharmacy) near ZIP 23666 for four 0.75 mg/0.5 mL pens (2 mL, four weekly doses, 28 days by the FDA label); free coupon

    28-day supply (dailymed.nlm.nih.gov)

    ≈ $1,037.34 per 30 days at this quoted rate

    A discount card, not insurance. Trulicity has no generic. Prices vary by pharmacy and location.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Ingredient-level FDA shortage report:No shortage reportedOpen record
    Advertised price as read on its own page (wellrx.com)
  • Trulicity (brand, all doses)

    GoodRx

    View
    ~$992/mo (goodrx.com/trulicity)

    ≈ $1,062.95 per 30 days

    Checked on goodrx.com

    Third-party report

    Top dose: same price at 4.5 mg

    Terms & source

    Advertised price: GoodRx coupon, lowest listed pharmacy price for one 4-pen carton at 0.75 mg; no generic

    28-day supply (lilly.com)

    ≈ $1,062.95 per 30 days at this quoted rate

    Top-dose terms: GoodRx's coupon price for one carton of four 4.5 mg pens.

    Trulicity has no generic. LillyDirect sells the same pens from $389 a month.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Ingredient-level FDA shortage report:No shortage reportedOpen record
    Advertised price as read on its own page (goodrx.com)

Read prices in context. Compare the same product, dose and payment terms; missing prices are not estimated.

How prices are compared

A prepaid monthly rate is not a monthly payment. Cost order uses current, recently checked quotes, converted to 30 days: by the supply a price buys where the seller states it in days, otherwise a monthly price with its plan length on record read as four weekly doses, a yearly membership in the price spread over twelve months. Introductory prices, ranges, prices with no plan length on record and separately billed fees are unranked references. Dose changes and added fees affect what you pay.

A listed maintenance dose is not a dosing recommendation.

Prices are self-pay cash figures a person pays, not pharmacy acquisition costs. They change often; each names its source. Every cash quote was checked on or after Nov 6, 2026. Compounded semaglutide and tirzepatide are prepared by pharmacies and are not FDA-approved. This is information, not medical advice.

Indications

Brands, formulations & approved uses

Trulicity

  • InjectionOnce weekly

    Glucose control in adults and children 10+ with type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.

    Prescribing information (pi.lilly.com) · Reviewed Nov 4, 2026

A once-weekly GLP-1 receptor agonist fused to an antibody fragment for an extended half-life.

Availability

Shortage status

No shortage reported

No matching shortage record was returned in the latest complete FDA check. Check the FDA database (accessdata.fda.gov).

Last complete check: Nov 17, 2026

Pricing

Pharmacy acquisition-cost reference

NADAC measures pharmacy acquisition costs per unit, not what you pay. Different strengths and concentrations are not equivalent monthly supplies.

View pharmacy and policy price references
  • Trulicity 0.75 MG/0.5 ML Pen
    NDC 00002143380
    Acquisition
    $487.6453/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Trulicity 1.5 MG/0.5 ML Pen
    NDC 00002143480
    Acquisition
    $487.62033/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Trulicity 3 MG/0.5 ML Pen
    NDC 00002223680
    Acquisition
    $487.56033/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Trulicity 4.5 MG/0.5 ML Pen
    NDC 00002318280
    Acquisition
    $487.41567/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026

Source: NADAC (Data.Medicaid.gov) (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d) · as of Nov 16, 2026

The ingredient index tracks pharmacy acquisition costs over windows up to 53 days long, not patient cash prices or just the presentation listed above. Each NDC starts at 100; we average its percentage change with the same NDCs at every point, so per-tablet and per-mL dollar prices are never averaged together. Incomplete days are omitted. “Flat” means a change smaller than 0.5%. Insufficient or truncated history shows no index.

NADAC is the average price pharmacies pay to acquire a drug, not the cash price at the counter. Compounded and cash prices, where shown, are labeled and are not FDA-approved list prices.
From FDA and CMS records

Dulaglutide: timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine toOn Medicare Part D, 2025
Trulicity4.5 mg from week 13about 5 daysNo, it is a biologicNot in the Orange Book582,333

How long each takes · Generics and patents · Who covers what

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

Showing the most recently effective indexed record for each brand and route combination. Alternate submissions and older records are linked below.

Trulicity

SUBCUTANEOUS · Eli Lilly and Company

Label effective · version 62Retrieved · Nov 17, 2026 UTCFull label on DailyMed (dailymed.nlm.nih.gov)Indexed source record (api.fda.gov)
Read indexed warnings and label text

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), and Nonclinical Toxicology ( 13.1 )] . TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of TRULICITY and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with TRULICITY [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] . WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. Dulaglutide causes thyroid C-cell tumors in rats. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined ( 5.1 , 13.1 ). TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors ( 4 , 5.1 ).

Contraindications

4 CONTRAINDICATIONS TRULICITY is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions ( 5.1 )] . Serious hypersensitivity reaction to dulaglutide or to any of the product components. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with TRULICITY [see Warnings and Precautions ( 5.4 )] . Patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 ( 4 ). Patients with a serious hypersensitivity reaction to dulaglutide or any of the product components ( 4 ).

Indications and uses

1 INDICATIONS AND USAGE TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. TRULICITY ® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated ( 1 ): As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Dosing and administration

2 DOSAGE AND ADMINISTRATION Adult Dosage ( 2.1 ) Recommended starting dosage is 0.75 mg injected subcutaneously once weekly. After 4 weeks, the dosage may be increased to 1.5 mg once weekly for additional glycemic control. If additional glycemic control is needed, increase dosage in 1.5 mg increments after at least 4 weeks on the current dosage. Maximum recommended dosage is 4.5 mg injected subcutaneously once weekly. Pediatric Dosage ( 2.2 ) Recommended starting dosage is 0.75 mg injected subcutaneously once weekly. If additional glycemic control is needed, increase dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage. Recommendations Regarding Missed Dose ( 2.3 ) If a dose is missed, administer the missed dose as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose. Important Administration Instructions ( 2.4 ) Administer once weekly at any time of day with or without food. Inject subcutaneously in the abdomen, thigh, or upper arm. 2.1 Adult Dosage The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )]. After 4 weeks, the dosage may be increased to 1.5 mg once weekly for additional glycemic control. If additional glycemic control is needed, increase the dosage in 1.5 mg increments after at least 4 weeks on the current dosage. The maximum recommended dosage is 4.5 mg injected subcutaneously once weekly. 2.2 Pediatric Dosage The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. If additional glycemic control is needed, increase the dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )] . 2.3 Recommendations Regarding Missed Dose If a dose is missed, instruct patients to administer the dose as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose. If less than 3 days remain before the next scheduled dose, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule. The day of weekly administration can be changed, if necessary, as long as the last dose was administered 3 or more days before the new day of administration. 2.4 Important Administration Instructions Prior to initiation, train patients and caregivers on proper injection technique [see Instructions for Use] . Administer TRULICITY once weekly, any time of day, with or without food. Inject TRULICITY subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites with each dose. Inspect TRULICITY visually before use. It should appear clear and colorless. Do not use TRULICITY if particulate matter or coloration is seen. When using TRULICITY with insulin, administer as separate injections and never mix. It is acceptable to inject TRULICITY and insulin in the same body region, but the injections should not be adjacent to each other.

Warnings and precautions

5 WARNINGS AND PRECAUTIONS Thyroid C-cell Tumors: See Boxed Warning ( 5.1 ). Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including TRULICITY. Discontinue if pancreatitis is suspected ( 5.2 ). Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin secretagogue or insulin may be necessary ( 5.3 ). Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) have occurred. Discontinue TRULICITY and promptly seek medical advice ( 5.4 ). Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion ( 5.5 ). Severe Gastrointestinal Adverse Reactions: Use may be associated with gastrointestinal adverse reactions, sometimes severe. TRULICITY is not recommended in patients with severe gastroparesis ( 5.6 ). Diabetic Retinopathy Complications: Have been reported in a cardiovascular outcomes trial. Monitor patients with a history of diabetic retinopathy ( 5.7 ). Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated ( 5.8 ). Pulmonary Aspiration During General Anesthesia or Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures ( 5.9 ). 5.1 Risk of Thyroid C-cell Tumors In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure [see Nonclinical Toxicology ( 13.1 )] . Glucagon-like peptide-1 (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures. It is unknown whether TRULICITY will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined. One case of MTC was reported in a patient treated with TRULICITY in a clinical trial. This patient had pretreatment calcitonin levels approximately 8 times the upper limit of normal (ULN). An additional case of C-cell hyperplasia with elevated calcitonin levels following treatment was reported in the cardiovascular outcomes trial (REWIND). Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans. TRULICITY is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of TRULICITY and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with TRULICITY. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated. 5.2 Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including TRULICITY [see Adverse Reactions ( 6 )] . After initiation of TRULICITY, observe patients carefully for signs and symptoms of acute pancreatitis which may include persistent or severe abdominal pain (sometimes radiating to the back) and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue TRULICITY and initiate appropriate management. 5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin Patients receiving TRULICITY in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions ( 6.1 ) and Drug Interactions ( 7 )]. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. 5.4 Hypersensitivity Reactions There have been postmarketing reports of serious hypersensitivity reactions including anaphylactic reactions and angioedema in patients treated with TRULICITY [see Adverse Reactions ( 6.2 )] . If a hypersensitivity reaction occurs, discontinue TRULICITY; treat promptly per standard of care, and monitor until signs and symptoms resolve. TRULICITY is contraindicated in patients with a previous serious hypersensitivity reaction to dulaglutide or to any of the components of TRULICITY. Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with TRULICITY. 5.5 Acute Kidney Injury Due to Volume Depletion There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, including TRULICITY [see Adverse Reactions ( 6.2 )] . The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions ( 6.1 )] . Monitor renal function in patients reporting adverse reactions to TRULICITY that could lead to volume depletion, especially during dosage initiation and escalation of TRULICITY. 5.6 Severe Gastrointestinal Adverse Reactions Use of TRULICITY has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions ( 6 )] . In the pool of placebo-controlled trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving TRULICITY (0.75 mg 2.2%, 1.5 mg 4.3%) than placebo (1.4%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. TRULICITY is not recommended in patients with severe gastroparesis. 5.7 Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy In a cardiovascular outcomes trial with a median follow up of 5.4 years involving patients with type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors, diabetic retinopathy complications occurred in patients treated with TRULICITY 1.5 mg (1.9%) and placebo (1.5%). These events were prospectively ascertained as a secondary composite endpoint. The proportion of patients with diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (TRULICITY 8.5%, placebo 6.2%) than among patients without a known history of diabetic retinopathy (TRULICITY 1%, placebo 1%). Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. 5.8 Acute Gallbladder Disease Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In a cardiovascular outcomes trial with a median follow up of 5.4 years, cholelithiasis occurred at a rate of 0.62/100 patient-years in TRULICITY-treated patients and 0.56/100 patient-years in placebo-treated patients after adjusting for prior cholecystectomy. Serious events of acute cholecystitis were reported in 0.5% and 0.3% of patients on TRULICITY and placebo respectively. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated. 5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation TRULICITY delays gastric emptying [see Clinical Pharmacology ( 12.2 )] . There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking TRULICITY, including whether modifying preoperative fasting recommendations or temporarily discontinuing TRULICITY could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking TRULICITY.

Drug interactions

7 DRUG INTERACTIONS Oral Medications: Delays gastric emptying and has the potential to reduce the rate of absorption of concomitantly administered oral medications ( 7.1 ). 7.1 Oral Medications TRULICITY delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications. The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of TRULICITY [see Dosage and Administration ( 2.1 )] . The delay is largest after the first dose and diminishes with subsequent doses. In clinical pharmacology studies, TRULICITY 1.5 mg did not affect the absorption of the tested orally administered medications to a clinically relevant degree [see Clinical Pharmacology ( 12.3 )] . There is limited experience with the use of concomitant medications in clinical trials with TRULICITY doses of 3 mg and 4.5 mg. Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY. 7.2 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin When initiating TRULICITY, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions ( 5.3 ) and Adverse Reactions ( 6.1 )].

Adverse reactions

6 ADVERSE REACTIONS The following serious reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors [see Warnings and Precautions ( 5.1 )] Acute Pancreatitis [see Warnings and Precautions ( 5.2 )] Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions ( 5.3 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.4 )] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions ( 5.5 )] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.6 )] Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy [see Warnings and Precautions ( 5.7 )] Acute Gallbladder Disease [see Warnings and Precautions ( 5.8 )] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions ( 5.9 )] Most common adverse reactions (incidence ≥5%) are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adverse Reactions in the Clinical Trials in Adults with Type 2 Diabetes Mellitus Pool of Adult Placebo-Controlled Trials for TRULICITY 0.75 mg and 1.5 mg Doses The data in Table 1 are derived from a pool of placebo-controlled trials and include 1,670 adult patients with type 2 diabetes mellitus exposed to TRULICITY with a mean duration of exposure of 23.8 weeks [see Clinical Studies ( 14 )] . The mean age of patients was 56 years, 1% were 75 years or older and 53% were male. The population was 69% White, 7% Black or African American, 13% Asian; 30% were of Hispanic or Latino ethnicity. At baseline, the population had diabetes for an average of 8 years, a mean HbA1c of 8.0%, and 2.5% of the population reported retinopathy. Baseline estimated renal function was normal or mildly impaired (eGFR ≥60 mL/min/1.73 m 2 ) in 96%. Table 1 shows adverse reactions, excluding hypoglycemia, occurring in ≥5% of TRULICITY treated adult patients and more commonly than placebo in a pool of placebo-controlled trials. Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials That Occurred in ≥5% of TRULICITY-Treated Adult Patients with Type 2 Diabetes Mellitus a Includes diarrhea, fecal volume increased, frequent bowel movements. b Includes retching, vomiting, vomiting projectile. c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain. d Includes fatigue, asthenia, malaise. Note: Percentages reflect the number of patients that reported at least 1 treatment-emergent occurrence of the adverse reaction. Adverse Reaction Placebo (N=568) % TRULICITY 0.75 mg (N=836) % TRULICITY 1.5 mg (N=834) % Nausea 5.3 12.4 21.1 Diarrhea a 6.7 8.9 12.6 Vomiting b 2.3 6.0 12.7 Abdominal Pain c 4.9 6.5 9.4 Decreased Appetite 1.6 4.9 8.6 Dyspepsia 2.3 4.1 5.8 Fatigue d 2.6 4.2 5.6 Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials, gastrointestinal (GI) adverse reactions occurred more frequently among patients who received TRULICITY compared to patients who received placebo (placebo 21%, 0.75 mg 32%, 1.5 mg 41%). A higher percentage of patients who received TRULICITY 0.75 mg (1.3%) and TRULICITY 1.5 mg (3.5%) discontinued treatment due to GI adverse reactions than patients who received placebo (0.2%). Investigators graded the severity of GI adverse reactions that occurred in those treated with 0.75 mg and 1.5 mg of TRULICITY as “mild” in 58% and 48% of cases, respectively, “moderate” in 35% and 42% of cases, respectively, or “severe” in 7% and 11% of cases, respectively. The following GI adverse reactions were reported more frequently in TRULICITY-treated patients than placebo -treated patients (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%). Adult Dose Ranging Trial for TRULICITY 3 mg and 4.5 mg Doses Table 2 shows adverse reactions occurring ≥5% in any of the treatment groups through 36 weeks in a clinical trial with 1842 adult patients with type 2 diabetes mellitus treated with TRULICITY 1.5 mg, 3 mg, or 4.5 mg subcutaneously once weekly as an add-on to metformin [see Clinical Studies ( 14.3 )] . The adverse reaction profile is consistent with previous clinical trials in adults. Table 2: Adverse Reactions That Occurred in ≥5% of TRULICITY-treated Adult Patients with Type 2 Diabetes Mellitus in a Clinical Trial through 36 Weeks a a Percentages reflect the number of patients that reported at least 1 treatment-emergent occurrence of the adverse reaction. Adverse Reaction TRULICITY 1.5 mg (N=612) % TRULICITY 3 mg (N=616) % TRULICITY 4.5 mg (N=614) % Nausea 13.4 15.6 16.4 Diarrhea 7.0 11.4 10.7 Vomiting 5.6 8.3 9.3 Dyspepsia 2.8 5.0 2.6 Other Adverse Reactions in Adults Hypoglycemia Table 3 summarizes the incidence of hypoglycemia in the placebo-controlled clinical studies in adult patients with type 2 diabetes mellitus: episodes with a glucose level <54 mg/dL with or without symptoms, and severe hypoglycemia, defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Table 3: Incidence (%) of Hypoglycemia in Adult Patients with Type 2 Diabetes Mellitus in Placebo-Controlled Trials Placebo TRULICITY 0.75 mg TRULICITY 1.5 mg Add-on to Metformin (26 weeks) N=177 N=302 N=304 Hypoglycemia with a glucose level <54 mg/dL 0 0.3 0.7 Severe hypoglycemia 0 0 0 Add-on to Metformin + Pioglitazone (26 weeks) N=141 N=280 N=279 Hypoglycemia with a glucose level <54 mg/dL 1.4 2.1 0 Severe hypoglycemia 0 0 0 Add-on to Glimepiride (24 weeks) N=60 - N=239 Hypoglycemia with a glucose level <54 mg/dL 0 - 3.3 Severe hypoglycemia 0 - 0 In Combination with Insulin Glargine ± Metformin (28 weeks) N=150 - N=150 Hypoglycemia with a glucose level <54 mg/dL 9.3 - 14.7 Severe hypoglycemia 0 - 0.7 Add-on to SGLT2i ± Metformin (24 weeks) N=140 N=141 N=142 Hypoglycemia with a glucose level <54 mg/dL 0.7 0.7 0.7 Severe hypoglycemia 0 0.7 0 Hypoglycemia was more frequent when TRULICITY was used in combination with a sulfonylurea or insulin than when used with non-secretagogues. In a 78-week adult clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 20% and 21% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea. Severe hypoglycemia occurred in 0% and 0.7% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea. In a 52-week adult clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 77% and 69% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin. Severe hypoglycemia occurred in 2.7% and 3.4% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin. Refer to Table 3 for the incidence of hypoglycemia in patients treated in combination with basal insulin glargine. In the clinical trial with adult patients on TRULICITY 1.5 mg, TRULICITY 3 mg, or TRULICITY 4.5 mg once weekly, as add-on to metformin, incidences of hypoglycemia (glucose level <54 mg/dL) through 36 weeks were 1.1%, 0.3%, and 1.1%, respectively, and incidences of severe hypoglycemia were 0.2%, 0%, and 0.2%, respectively. Cholelithiasis and Cholecystitis In a cardiovascular outcomes trial in adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors with a median follow up of 5.4 years [see Clinical Studies 14.5 ] , cholelithiasis occurred at a rate of 0.62/100 patient-years in TRULICITY-treated patients and 0.56/100 patient-years in placebo-treated patients after adjusting for prior cholecystectomy. Serious events of acute cholecystitis were reported in 0.5% and 0.3% of patients on TRULICITY and placebo respectively. Heart Rate Increase and Tachycardia-Related Adverse Reactions In adult patients, TRULICITY 0.75 mg and 1.5 mg resulted in a mean increase in heart rate (HR) of 2-4 beats per minute (bpm). Adverse reactions of sinus tachycardia were reported more frequently in patients exposed to TRULICITY. Sinus tachycardia was reported in 3.0%, 2.8%, and 5.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Persistence of sinus tachycardia (reported at more than 2 visits) was reported in 0.2%, 0.4% and 1.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of ≥15 beats per minute, were reported in 0.7%, 1.3% and 2.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Hypersensitivity Systemic hypersensitivity adverse reactions, sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling), occurred in 0.5% of adult patients on TRULICITY in clinical studies. Injection-site Reactions In the placebo-controlled studies in adults, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of TRULICITY-treated patients and in 0.0% of placebo-treated patients. PR Interval Prolongation and Adverse Reactions of First-Degree Atrioventricular (AV) Block A mean increase from baseline in PR interval of 2-3 milliseconds was observed in TRULICITY-treated adult patients in contrast to a mean decrease of 0.9 milliseconds in placebo-treated patients. The adverse reaction of first-degree AV block occurred more frequently in patients treated with TRULICITY than placebo (0.9%, 1.7% and 2.3% for placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively). On electrocardiograms, a PR interval increase to at least 220 milliseconds was observed in 0.7%, 2.5% and 3.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Acute Pancreatitis In a pooled analysis from the original registration studies, 12 (3.4 cases per 1,000 patient years) pancreatitis-related adverse reactions were reported in patients exposed to TRULICITY versus 3 in non-incretin comparators (2.7 cases per 1000 patient years). An analysis of adjudicated events revealed 5 cases of confirmed pancreatitis in patients exposed to TRULICITY (1.4 cases per 1,000 patient years) versus 1 case in non-incretin comparators (0.88 cases per 1,000 patient years). Based on an analysis of adjudicated events in a clinical trial evaluating Trulicity 1.5 mg, 3 mg, or 4.5 mg once weekly, pancreatitis occurred in 1 patient exposed to TRULICITY 1.5 mg (0.2%), in 2 patients exposed to TRULICITY 3 mg (0.3%), and 3 patients exposed to TRULICITY 4.5 mg (0.5%). Amylase and Lipase Increase Adult patients exposed to TRULICITY had mean increases from baseline in lipase and/or pancreatic amylase of 14% to 20%, while placebo-treated patients had mean increases of up to 3%. Adverse Reactions in the Clinical Trial of Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus TRULICITY was administered to 150 pediatric patients 10 years of age and older with type 2 diabetes mellitus for a mean duration of 41.3 weeks [ see Clinical Studies ( 14.6 ) ]. The mean age was 14.5 years and 71% of patients were female. Overall, 55% were White, 15% were Black or African American, 12% were Asian, 10% were American Indian or Alaska Native, 5% were other races, and 3% had unknown race. Additionally, 55% were Hispanic or Latino, 42% were not Hispanic or Latino, and 3% had unknown ethnicity. At baseline, the mean duration of type 2 diabetes mellitus was 2 years, mean HbA1c was 8.1%, mean weight was 90.5 kg and mean BMI was 34.1 kg/m 2 . The safety profile in pediatric patients treated with TRULICITY 0.75 mg and 1.5 mg subcutaneously once-weekly was consistent with that described above for adult patients with type 2 diabetes mellitus with the exception of injection site reactions. In pediatric patients, the incidence of injection site reactions was 3.9% (2 patients) in the TRULICITY 0.75 mg group, 3.8% (2 patients) in the TRULICITY 1.5 mg group, and 2.0% (1 patient) in the placebo group. 6.2 Postmarketing Experience The following additional adverse reactions have been reported during post-approval use of TRULICITY. Because these events are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal: acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction Hepatobiliary: cholecystitis, cholelithiasis requiring cholecystectomy, cholestasis, elevation of liver enzymes, hepatitis Hypersensitivity: anaphylactic reactions, angioedema Neurologic : dysgeusia, dysesthesia Pulmonary: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation Renal: acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis Skin and Subcutaneous Tissue: alopecia

Clinical studies

14 CLINICAL STUDIES 14.1 Overview of Clinical Trials TRULICITY has been studied in adults as monotherapy and in combination with metformin, sulfonylurea, metformin and sulfonylurea, metformin and thiazolidinedione, sodium-glucose co-transporter-2 inhibitors (SGLT2i) with or without metformin, basal insulin with or without metformin, and prandial insulin with or without metformin. TRULICITY has also been studied in patients with type 2 diabetes mellitus and moderate to severe renal impairment. Dose escalation was performed in one trial in adults with TRULICITY doses up to 4.5 mg added to metformin. All other clinical studies in adults evaluated TRULICITY 0.75 mg and 1.5 mg without dose escalation; patients were initiated and maintained on either 0.75 mg or 1.5 mg for the duration of the trials [see Clinical Studies ( 14.2 , 14.3 , 14.4 )] . TRULICITY 0.75 mg and 1.5 mg was studied in pediatric patients 10 years of age and older with type 2 diabetes in combination with or without metformin and/or basal insulin treatment [see Clinical Studies ( 14.6 )] . In patients with type 2 diabetes mellitus, TRULICITY produced reductions from baseline in HbA1c compared to placebo. No overall differences in glycemic effectiveness were observed across demographic subgroups (age, gender, race/ethnicity, duration of diabetes). A cardiovascular outcomes trial was conducted in adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors. Patients were randomized to TRULICITY 1.5 mg or placebo both added to standard of care. TRULICITY significantly reduced the risk of first occurrence of primary composite endpoint of CV death, non-fatal MI, or non-fatal stroke [see Clinical Studies ( 14.5 )] . 14.2 Glycemic Control Monotherapy Trials in Adults with Type 2 Diabetes Mellitus In a double-blind trial with primary endpoint at 26 weeks, 807 adult patients inadequately treated with diet and exercise, or with diet and exercise and one antidiabetic agent used at submaximal dose, were randomized to TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or metformin 1500 to 2000 mg/day following a two-week washout. Seventy-five percent (75%) of the randomized population were treated with one antidiabetic agent at the screening visit. Most patients previously treated with an antidiabetic agent were receiving metformin (~90%) at a median dose of 1000 mg daily and approximately 10% were receiving a sulfonylurea. Patients had a mean age of 56 years and a mean duration of type 2 diabetes of 3 years. Forty-four percent were male. The White, Black and Asian race accounted for 74%, 7% and 8% of the population, respectively. Twenty-nine percent of the trial population were from the US. Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in reduction in HbA1c from baseline at 26-weeks ( Table 4 ). The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and metformin excluded the pre-specified non-inferiority margin of 0.4%. Table 4: Results at Week 26 in a Trial of TRULICITY as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus a Abbreviation: HbA1c = hemoglobin A1c. a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 26, primary efficacy was missing for 10%, 12% and 14% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and metformin, respectively. b Least-squares mean adjusted for baseline value and other stratification factors. ‡ Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 265 individuals in each of the treatment arms. 26-Week Primary Time Point TRULICITY 0.75 mg TRULICITY 1.5 mg Metformin 1500-2000 mg Intent-to-Treat (ITT) Population (N) ‡ 270 269 268 HbA1c (%) (Mean) Baseline 7.6 7.6 7.6 Change from baseline b -0.7 -0.8 -0.6 Fasting Serum Glucose (mg/dL) (Mean) Baseline 161 164 161 Change from baseline b -26 -29 -24 Body Weight (kg) (Mean) Baseline 91.8 92.7 92.4 Change from baseline b -1.4 -2.3 -2.2 14.3 Glycemic Control Combination Therapy Trials in Adults with Type 2 Diabetes Mellitus Sitagliptin-Controlled Trial (Add-on to Metformin) In this placebo-controlled, double-blind trial with primary endpoint at 52 weeks, 972 adult patients were randomized to placebo, TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or sitagliptin 100 mg/day (after 26 weeks, patients in the placebo treatment group received blinded sitagliptin 100 mg/day for the remainder of the trial), all as add-on to metformin. Randomization occurred after an 11-week lead-in period to allow for a metformin titration period, followed by a 6-week glycemic stabilization period. Patients had a mean age of 54 years; mean duration of type 2 diabetes of 7 years; 48% were male; race: White, Black and Asian were 53%, 4% and 27%, respectively; and 24% of the trial population were in the US. At the 26-week placebo-controlled time point, the HbA1c change was 0.1%, -1.0%, -1.2%, and -0.6% for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively. The percentage of patients who achieved HbA1c <7.0% was 22%, 56%, 62% and 39% for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively. At 26 weeks, there was a mean weight reduction of 1.4 kg, 2.7 kg, 3.0 kg, and 1.4 kg for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively. There was a mean reduction of fasting glucose of 9 mg/dL, 35 mg/dL, 41 mg/dL, and 18 mg/dL for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively. Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a statistically significant reduction in HbA1c compared to placebo (at 26 weeks) and compared to sitagliptin (at 26 and 52 weeks), all in combination with metformin ( Table 5 and Figure 3 ). Table 5: Results at Week 52 of TRULICITY Compared to Sitagliptin used as Add-On to Metformin in Adult Patients with Type 2 Diabetes Mellitus a Abbreviations: HbA1c = hemoglobin A1c. a All ITT patients randomized after the dose-finding portion of the trial. Last observation carried forward (LOCF) was used to impute missing data. At Week 52 primary efficacy was missing for 15%, 19%, and 20% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and sitagliptin, respectively. b Least-squares (LS) mean adjusted for baseline value and other stratification factors. ‡ Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 276, 277, and 270 individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and sitagliptin, respectively. †† Multiplicity adjusted 1-sided p-value <0.001, for superiority of TRULICITY compared to sitagliptin, assessed only for HbA1c. ## p<0.001 TRULICITY compared to sitagliptin, assessed only for HbA1c <7.0%. 52-Week Primary Time Point TRULICITY 0.75 mg TRULICITY 1.5 mg Sitagliptin 100 mg Intent-to-Treat (ITT) Population (N) ‡ 281 279 273 HbA1c (%) (Mean) Baseline 8.2 8.1 8.0 Change from baseline b -0.9 -1.1 -0.4 Difference from sitagliptin b (95% CI) -0.5 (-0.7, -0.3) †† -0.7 (-0.9, -0.5) †† - Percentage of patients HbA1c <7.0% 49 ## 59 ## 33 Fasting Plasma Glucose (mg/dL) (Mean) Baseline 174 173 171 Change from baseline b -30 -41 -14 Difference from sitagliptin b (95% CI) -15 (-22, -9) -27 (-33, -20) - Body Weight (kg) (Mean) Baseline 85.5 86.5 85.8 Change from baseline b -2.7 -3.1 -1.5 Difference from sitagliptin b (95% CI) -1.2 (-1.8, -0.6) -1.5 (-2.1, -0.9) - Mean HbA1c adjusted for baseline HbA1c and country. Number of patients with observed data Placebo 139 108 TRULICITY 0.75 mg 281 258 238 TRULICITY 1.5 mg 279 249 225 Sitagliptin 273 241 219 Figure 3: Adjusted Mean HbA1c at each Time Point (ITT, MMRM) and at Week 52 (ITT, LOCF) in Adult Patients with Type 2 Diabetes Mellitus Figure 3 Dosage Ranging Trial of TRULICITY 1.5, 3 mg, and 4.5 mg (Add-on to Metformin) In this parallel-arm, double-blind trial with primary endpoint at 36 weeks, a total of 1842 adult patients were randomized 1:1:1 to TRULICITY 1.5 mg, TRULICITY 3 mg, or TRULICITY 4.5 mg once weekly, all as add-on to metformin (NCT03495102). Following randomization, all patients received TRULICITY 0.75 mg once weekly. The dose was increased every 4 weeks to the next higher dose until the patients reached their assigned dose (1.5 mg, 3 mg, or 4.5 mg). Patients were to remain on the assigned study dose for the duration of the trial. Patients had a mean age of 57.1 years; a mean duration of type 2 diabetes of 7.6 years; 51.2% were male; race: White, Black, and Asian were 85.8%, 4.5%, and 2.4%, respectively; and 27.6% of the trial population was in the US. At 36 weeks, treatment with TRULICITY 4.5 mg resulted in a statistically significant reduction in HbA1c and in body weight compared to TRULICITY 1.5 mg ( Table 6 and Figure 4 ). Table 6. Results at Week 36 of TRULICITY 1.5 mg Compared to 3 mg and 4.5 mg as Add-On to Metformin in Adult Patients with Type 2 Diabetes Mellitus a Abbreviations: HbA1c = hemoglobin A1c a Intent-to-treat population. At Week 36, primary efficacy was missing for 7%, 7%, and 6% of individuals treated with TRULICITY 1.5 mg, TRULICITY 3 mg, and TRULICITY 4.5 mg, respectively. b Least-squares mean adjusted for baseline value and other stratification factors. Missing data were imputed using multiple imputation. c Patients with missing HbA1c data at Week 36 were considered as not achieving HbA1c target. ^ p=0.0001 for superiority compared to TRULICITY 1.5 mg, overall type I error controlled. ^^ p<0.0001 for superiority compared to TRULICITY 1.5 mg, overall type I error controlled. 36-Week Primary Time Point TRULICITY 1.5 mg TRULICITY 3 mg TRULICITY 4.5 mg Intent-to-Treat (ITT) Population (N) 612 616 614 HbA1c (%) (Mean) Baseline 8.6 8.6 8.6 Change from baseline b -1.5 -1.6 -1.8 Difference from 1.5 mg b (95% CI) -0.1 (-0.2, 0.0) -0.2 (-0.4, -0.1) ^ Percentage of patients HbA1c <7.0% c 50 56 62 Fasting Serum Glucose (mg/dL) (Mean) Baseline 185 184 183 Change from baseline b -45 -46 -51 Difference from 1.5 mg b (95% CI) - 2 (-7, 3) -6 (-11, -2) Body Weight (kg) (Mean) Baseline 95.5 96.3 95.4 Change from baseline b -3.0 -3.8 -4.6 Difference from 1.5 mg b (95% CI) -0.9 (-1.4, -0.4) -1.6 (-2.2, -1.1) ^^ Number of patients with observed data TRULICITY 1.5 mg 612 567 TRULICITY 3 mg 616 572 TRULICITY 4.5 mg 614 575 Observed mean HbA1c at scheduled visits and retrieved dropout multiple imputation (MI) based estimate at week 36. Figure 4: Mean HbA1c at each Time Point (ITT) and at Week 36 (ITT, MI) Figure 4 Placebo-Controlled Trial (Add-on to Sulfonylurea) In this 24-week placebo-controlled, double-blind trial, 299 adult patients were randomized to and received placebo or once weekly TRULICITY 1.5 mg, both as add-on to glimepiride. Patients had a mean age of 58 years; mean duration of type 2 diabetes of 8 years; 44% were male; race: White, Black, and Asian were 83%, 4%, and 2%, respectively; and 24% of the trial population were in the US. At 24 weeks, treatment with once weekly TRULICITY 1.5 mg resulted in a statistically significant reduction in HbA1c compared to placebo ( Table 7 ). Table 7: Results at Week 24 of TRULICITY Compared to Placebo as Add-On to Glimepiride in Adult Patients with Type 2 Diabetes Mellitus a Abbreviations: HbA1c = hemoglobin A1c. a Intent-to-treat population. Data post-onset of rescue therapy are treated as missing. At Week 24 primary efficacy was missing for 10% and 12% of individuals randomized to TRULICITY 1.5 mg and placebo, respectively. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. Placebo multiple imputation, with respect to the baseline values, was used to model a wash-out of the treatment effect for patients having missing Week 24 data. c Patients with missing HbA1c data at Week 24 were considered as non-responders. †† p<0.001 for superiority of TRULICITY 1.5 mg compared to placebo, overall type I error controlled. 24-Week Primary Time Point Placebo TRULICITY 1.5 mg Intent-to-Treat (ITT) Population (N) 60 239 HbA1c (%) (Mean) Baseline 8.4 8.4 Change from baseline b -0.3 -1.3 Difference from placebo b (95% CI) -1.1 (-1.4, -0.7) †† Percentage of patients HbA1c <7.0% c 17 50 †† Fasting Serum Glucose (mg/dL) (Mean) Baseline 175 178 Change from baseline b 2 -28 Difference from placebo b (95% CI) -30 (-44, -15) †† Body Weight (kg) (Mean) Baseline 89.5 84.5 Change from baseline b -0.2 -0.5 Difference from placebo b (95% CI) -0.4 (-1.2, 0.5) Placebo- and Exenatide-Controlled Trial (Add-on to Metformin and Thiazolidinedione) In this placebo-controlled trial with primary endpoint at 26 weeks, 976 adult patients were randomized to and received placebo, TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or exenatide 10 mcg BID, all as add-on to maximally tolerated doses of metformin (≥1500 mg per day) and pioglitazone (up to 45 mg per day). Exenatide treatment group assignment was open-label while the treatment assignments to placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg were blinded. After 26 weeks, patients in the placebo treatment group were randomized to either TRULICITY 0.75 mg once weekly or TRULICITY 1.5 mg once weekly to maintain blinding. Randomization occurred after a 12-week lead-in period; during the initial 4 weeks of the lead-in period, patients were titrated to maximally tolerated doses of metformin and pioglitazone; this was followed by an 8-week glycemic stabilization period prior to randomization. Patients randomized to exenatide started at a dose of 5 mcg BID for 4 weeks and then were escalated to 10 mcg BID. Patients had a mean age of 56 years; mean duration of type 2 diabetes of 9 years; 58% were male; race: White, Black and Asian were 74%, 8% and 3%, respectively; and 81% of the trial population were in the US. Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a statistically significant reduction in HbA1c compared to placebo (at 26 weeks) and compared to exenatide at 26 weeks ( Table 8 and Figure 5 ). Over the 52-week trial period, the percentage of patients who required glycemic rescue was 8.9% in the TRULICITY 0.75 mg once weekly + metformin and pioglitazone treatment group, 3.2% in the TRULICITY 1.5 mg once weekly + metformin and pioglitazone treatment group, and 8.7% in the exenatide BID + metformin and pioglitazone treatment group. Table 8: Results at Week 26 of TRULICITY Compared to Placebo and Exenatide, All as Add-On to Metformin and Thiazolidinedione in Adult Patients with Type 2 Diabetes Mellitus a Abbreviations: BID = twice daily; HbA1c = hemoglobin A1c. a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 26, primary efficacy was missing for 23%, 10%, 7% and 12% of individuals randomized to placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and exenatide, respectively. b Least-squares (LS) mean adjusted for baseline value and other stratification factors. ‡ Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 119, 269, 271 and 266 individuals randomized to placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and exenatide, respectively. ‡‡ Multiplicity adjusted 1-sided p-value <0.001, for superiority of TRULICITY compared to placebo, assessed only for HbA1c. †† Multiplicity adjusted 1-sided p-value <0.001, for superiority of TRULICITY compared to exenatide, assessed only for HbA1c. ** p<0.001 TRULICITY compared to placebo, assessed only for HbA1c <7.0%. ## p<0.001 TRULICITY compared to exenatide, assessed only for HbA1c <7.0%. 26-Week Primary Time Point Placebo TRULICITY 0.75 mg TRULICITY 1.5 mg Exenatide 10 mcg BID Intent-to-Treat (ITT) Population (N) ‡ 141 280 279 276 HbA1c (%) (Mean) Baseline 8.1 8.1 8.1 8.1 Change from baseline b -0.5 -1.3 -1.5 -1.0 Difference from placebo b (95% CI) - -0.8 (-1.0, -0.7) ‡‡ -1.1 (-1.2, -0.9) ‡‡ - Difference from exenatide b (95% CI) - -0.3 (-0.4, -0.2) †† -0.5 (-0.7, -0.4) †† - Percentage of patients HbA1c <7.0% 43 66** , ## 78** , ## 52 Fasting Serum Glucose (mg/dL) (Mean) Baseline 166 159 162 164 Change from baseline b -5 -34 -42 -24 Difference from placebo b (95% CI) - -30 (-36, -23) -38 (-45, -31) - Difference from exenatide b (95% CI) - -10 (-15, -5) -18 (-24, -13) - Body Weight (kg) (Mean) Baseline 94.1 95.5 96.2 97.4 Change from baseline b 1.2 0.2 -1.3 -1.1 Difference from placebo b (95% CI) - -1.0 (-1.8, -0.3) -2.5 (-3.3, -1.8) - Difference from exenatide b (95% CI) - 1.3 (0.6, 1.9) -0.2 (-0.9, 0.4) - Mean HbA1c adjusted for baseline HbA1c and country. Number of patients with observed data Placebo 141 108 TRULICITY 0.75 mg 280 251 TRULICITY 1.5 mg 279 259 Exenatide 276 242 Figure 5: Adjusted Mean HbA1c at Each Time Point (ITT, MMRM) and at Week 26 (ITT, LOCF) Figure 5 Placebo-Controlled Trial (Add-on to SGLT2i, with or without Metformin) In this 24-week placebo-controlled, double-blind trial, 423 adult patients were randomized to and received TRULICITY 0.75 mg, TRULICITY 1.5 mg, or placebo, as add-on to sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy (96% with and 4% without metformin). Trulicity was administered once weekly, and SGLT2i was administered according to the local country label. Patients had a mean age of 57 years; mean duration of type 2 diabetes of 9.4 years; 50% were male; race: White, Black, and Asian were 89%, 3%, and 0.2%, respectively; and 21% of the trial population was in the US. At 24 weeks, treatment with once weekly TRULICITY 0.75 mg and 1.5 mg resulted in a statistically significant reduction from baseline in HbA1c compared to placebo ( Table 9 ). The mean baseline body weight was 90.5, 91.1, and 92.9 kg in the placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg groups, respectively. The mean changes from baseline in body weight at Week 24 were -2.0, -2.5, and -2.9 kg for placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg, respectively. The difference from placebo (95% CI) was -0.9 kg (-1.7, -0.1) for TRULICITY 1.5 mg. Table 9: Results at Week 24 of TRULICITY as Add-on to SGLT2i in Adult Patients with Type 2 Diabetes Mellitus a Abbreviations: HbA1c = hemoglobin A1c; SGLT2i = sodium-glucose co-transporter-2 inhibitors. a Intent-to-treat population. At Week 24, primary efficacy was missing for 3%, 4%, and 6% of individuals treated with placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg, respectively. b Least-squares mean adjusted for baseline value and other stratification factors. Placebo multiple imputation, using baseline and 24-week values from the placebo arm, was applied to model a washout of the treatment effect for patients missing 24-week values (HbA1c, fasting serum glucose, and body weight). c Patients with missing HbA1c data at Week 24 were considered as non-responders. †† p<0.001 for superiority of TRULICITY compared to placebo, overall type I error controlled. 24-Week Primary Time Point Placebo TRULICITY 0.75 mg TRULICITY 1.5 mg Intent-to-Treat (ITT) Population (N) 140 141 142 HbA1c (%) (Mean) Baseline 8.1 8.1 8.0 Change from baseline b -0.6 -1.2 -1.3 Difference from placebo b (95% CI) - -0.7 (-0.8, -0.5) †† -0.8 (-0.9, -0.6) †† Percentage of patients HbA1c <7.0% c 31 59 †† 67 †† Fasting Serum Glucose (mg/dL) (Mean) Baseline 153 162 161 Change from baseline b -6 -25 -30 Difference from placebo b (95% CI) - -19 (-25, -13) -24 (-30, -18) †† Insulin Glargine Controlled Trial (Add-on to Metformin and Sulfonylurea) In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 52 weeks, 807 adult patients were randomized to and received TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or insulin glargine once daily, all as add-on to maximally tolerated doses of metformin and glimepiride. Randomization occurred after a 10-week lead-in period; during the initial 2 weeks of the lead-in period, patients were titrated to maximally tolerated doses of metformin and glimepiride. This was followed by a 6- to 8-week glycemic stabilization period prior to randomization. Patients randomized to insulin glargine were started on a dose of 10 units once daily. Insulin glargine dose adjustments occurred twice weekly for the first 4 weeks of treatment based on self-measured fasting plasma glucose (FPG), followed by once weekly titration through Week 8 of treatment, utilizing an algorithm that targeted a fasting plasma glucose of <100 mg/dL. Only 24% of patients were titrated to goal at the 52-week primary endpoint. The dose of glimepiride could be reduced or discontinued after randomization (at the discretion of the investigator) in the event of persistent hypoglycemia. The dose of glimepiride was reduced or discontinued in 28%, 32%, and 29% of patients randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg, and glargine. Patients had a mean age of 57 years; mean duration of type 2 diabetes of 9 years; 51% were male; race: White, Black and Asian were 71%, 1% and 17%, respectively; and 0% of the trial population were in the US. Treatment with TRULICITY once weekly resulted in a reduction in HbA1c from baseline at 52 weeks when used in combination with metformin and sulfonylurea ( Table 10 ). The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4%. Table 10: Results at Week 52 of TRULICITY Compared to Insulin Glargine, Both as Add-on to Metformin and Sulfonylurea in Adult Patients with Type 2 Diabetes Mellitus a Abbreviations: HbA1c = hemoglobin A1c. a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 52, primary efficacy was missing for 17%, 13% and 12% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and glargine, respectively. b Least-squares (LS) mean adjusted for baseline value and other stratification factors. ‡ Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 267, 263 and 259 individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg, and glargine, respectively. 52-Week Primary Time Point TRULICITY 0.75 mg TRULICITY 1.5 mg Insulin Glargine Intent-to-Treat (ITT) Population (N) ‡ 272 273 262 HbA1c (%) (Mean) Baseline 8.1 8.2 8.1 Change from baseline b -0.8 -1.1 -0.6 Fasting Serum Glucose (mg/dL) (Mean) Baseline 161 165 163 Change from baseline b -16 -27 -32 Difference from insulin glargine b (95% CI) 16 (9, 23) 5 (-2, 12) - Body Weight (kg) (Mean) Baseline 86.4 85.2 87.6 Change from baseline b -1.3 -1.9 1.4 Difference from insulin b (95% CI) -2.8 (-3.4, -2.2) -3.3 (-3.9, -2.7) - Placebo-Controlled Trial (Add-on to Basal Insulin, with or without Metformin) In this 28-week placebo-controlled, double-blind trial, 300 adult patients were randomized to placebo or once weekly TRULICITY 1.5 mg, as add-on to titrated basal insulin glargine (with or without metformin). Patients had a mean age of 60 years; mean duration of type 2 diabetes of 13 years; 58% were male; race: White, Black, and Asian were 94%, 4%, and 0.3%, respectively; and 20% of the trial population was in the US. The mean starting dose of insulin glargine was 37 units/day for patients receiving placebo and 41 units/day for patients receiving TRULICITY 1.5 mg. At randomization, the initial insulin glargine dose in patients with HbA1c <8.0% was reduced by 20%. At 28 weeks, treatment with once weekly TRULICITY 1.5 mg resulted in a statistically significant reduction in HbA1c compared to placebo ( Table 11 ). Table 11: Results at Week 28 of TRULICITY Compared to Placebo as Add-On to Basal Insulin in Adult Patients with Type 2 Diabetes Mellitus a Abbreviations: HbA1c = hemoglobin A1c. a Intent-to-treat population. At Week 28, primary efficacy was missing for 12% and 8% of individuals randomized to placebo and TRULICITY 1.5 mg, respectively. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. Placebo multiple imputation, with respect to baseline values, was used to model a wash-out of the treatment effect for patients having missing Week 28 data. c Patients with missing HbA1c data at Week 28 were considered as non-responders. †† p<0.001 for superiority of TRULICITY 1.5 mg compared to placebo, overall type I error controlled. † p≤0.005 for superiority of TRULICITY 1.5 mg compared to placebo, overall type I error controlled. 28-Week Primary Time Point Placebo TRULICITY 1.5 mg Intent-to-Treat (ITT) Population (N) 150 150 HbA1c (%) (Mean) Baseline 8.3 8.4 Change from baseline b -0.7 -1.4 Difference from placebo b (95% CI) -0.7 (-0.9, -0.5) †† Percentage of patients HbA1c <7.0% c 33 67 †† Fasting Serum Glucose (mg/dL) (Mean) Baseline 156 157 Change from baseline b -30 -44 Difference from placebo b (95% CI) -14 (-23, -4) † Body Weight (kg) (Mean) Baseline 92.6 93.3 Change from baseline b 0.8 -1.3 Difference from placebo b (95% CI) -2.1 (-2.9, -1.4) †† Insulin Glargine-Controlled Trial (Combination with Prandial Insulin, with or without Metformin) In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 26 weeks, 884 adult patients on 1 or 2 insulin injections per day were enrolled. Randomization occurred after a 9-week lead-in period; during the initial 2 weeks of the lead-in period, patients continued their pre-trial insulin regimen but could be initiated and/or up-titrated on metformin, based on investigator discretion; this was followed by a 7-week glycemic stabilization period prior to randomization. At randomization, patients discontinued their pre-trial insulin regimen and were randomized to TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or insulin glargine once daily, all in combination with prandial insulin lispro 3 times daily, with or without metformin. Insulin lispro was titrated in each arm based on preprandial and bedtime glucose, and insulin glargine was titrated to a fasting plasma glucose goal of <100 mg/dL. Only 36% of patients randomized to glargine were titrated to the fasting glucose goal at the 26-week primary timepoint. Patients had a mean age of 59 years; mean duration of type 2 diabetes of 13 years; 54% were male; race: White, Black and Asian were 79%, 10% and 4%, respectively; and 33% of the trial population were in the US. Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a reduction in HbA1c from baseline. The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4% ( Table 12 ). Table 12: Results at Week 26 of TRULICITY Compared to Insulin Glargine, Both in Combination with Insulin Lispro in Adult Patients with Type 2 Diabetes Mellitus a Abbreviation: HbA1c = hemoglobin A1c a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 26, primary efficacy was missing for 14%, 15%, and 14% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and glargine, respectively. b Least-squares (LS) mean adjusted for baseline value and other stratification factors. ‡ Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 275, 273 and 276 individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg, and glargine, respectively. 26-Week Primary Time Point TRULICITY 0.75 mg TRULICITY 1.5 mg Insulin Glargine Intent-to-Treat (ITT) Population (N) ‡ 293 295 296 HbA1c (%) (Mean) Baseline 8.4 8.5 8.5 Change from baseline b -1.6 -1.6 -1.4 Fasting Serum Glucose (mg/dL) (Mean) Baseline 150 157 154 Change from baseline b 4 -5 -28 Difference from insulin glargine b (95% CI) 32 (24, 41) 24 (15, 32) - Body Weight (kg) (Mean) Baseline 91.7 91.0 90.8 Change from baseline b 0.2 -0.9 2.3 Difference from insulin glargine b (95% CI) -2.2 (-2.8, -1.5) -3.2 (-3.8, -2.6) - 14.4 Glycemic Control Trials in Adults with Type 2 Diabetes Mellitus and Moderate to Severe Chronic Kidney Disease In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 26 weeks, a total of 576 adult patients with type 2 diabetes were randomized and treated to compare TRULICITY 0.75 mg and 1.5 mg with insulin glargine (NCT01621178). Patients on insulin and other antidiabetic therapy (e.g., oral antidiabetic drugs, pramlintide) had non-insulin therapies discontinued and had their insulin dose adjusted for 12 weeks prior to randomization. Patients on insulin therapy alone maintained a stable insulin dose for 3 weeks prior to randomization. At randomization, patients discontinued their pre-trial insulin regimen and patients were randomized to TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or insulin glargine once daily, all in combination with prandial insulin lispro. For patients randomized to insulin glargine, the initial insulin glargine dose was based on the basal insulin dose prior to randomization. Insulin glargine was allowed to be titrated with a fasting plasma glucose goal of ≤150 mg/dL. Insulin lispro was allowed to be titrated with a preprandial and bedtime glucose goal of ≤180 mg/dL. Patients had a mean age of 65 years; a mean duration of type 2 diabetes of 18 years; 52% were male; race: White, Black, and Asian were 69%, 16%, and 3%, respectively; and 32% of the trial population were in the US. At baseline, overall mean eGFR was 38 mL/min/1.73 m 2 , 30% of patients had eGFR <30 mL/min/1.73 m 2 , and 45% of patients had macroalbuminuria. Patients on over 70 units/day of basal insulin were excluded from the trial. Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a reduction in HbA1c at 26-weeks from baseline. The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4%. Mean fasting plasma glucose increased in the TRULICITY arms ( Table 13 ). Mean baseline body weight was 90.9 kg, 88.1 kg, and 88.2 kg in the TRULICITY 0.75 mg, TRULICITY 1.5 mg, and insulin glargine arms, respectively. The mean changes from baseline at Week 26 were -1.1, -2, and 1.9 kg in the TRULICITY 0.75 mg, TRULICITY 1.5 mg, and insulin glargine arms, respectively. Table 13: Results at Week 26 of TRULICITY Compared to Insulin Glargine, Both in Combination with Insulin Lispro, in Patients with Moderate to Severe Chronic Kidney Disease in Adult Patients with Type 2 Diabetes Mellitus a Abbreviation: HbA1c = hemoglobin A1c a Intent-to-treat population (all randomized and treated patients) was used in the analysis regardless of discontinuation of study drug or initiation of rescue therapy. At Week 26, primary efficacy was missing for 12%, 15%, and 9% of individuals randomized to and treated with TRULICITY 0.75 mg, TRULICITY 1.5 mg, and insulin glargine, respectively. Missing data were imputed using multiple imputation within treatment group. b Least-squares (LS) mean from ANCOVA pattern mixture model adjusted for baseline value and other stratification factors. 26-Week Primary Time Point TRULICITY 0.75 mg TRULICITY 1.5 mg Insulin Glargine Intent-to-Treat Population (N) 190 192 194 HbA1c (%) (Mean) Baseline 8.6 8.6 8.6 Change from baseline b -0.9 -1.0 -1.0 Difference from insulin glargine b (95% CI) 0.0 (-0.2, 0.3) -0.1 (-0.3, 0.2) Percentage of patients HbA1c <8.0% 73 75 74 Fasting Serum Glucose (mg/dL) (Mean) Baseline 167 161 170 Change from baseline b 6 14 -23 Difference from insulin glargine b (95% CI) 30 (16, 43) 37 (24, 50) 14.5 Cardiovascular Outcomes Trial in Adults with Type 2 Diabetes Mellitus and Cardiovascular Disease or Multiple Cardiovascular Risk Factors The REWIND trial (NCT01394952) was a multi-national, multi-center, randomized, placebo-controlled, double-blind trial. In this trial, 9901 adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors were randomized to TRULICITY 1.5 mg or placebo both added to standard of care. The median follow-up duration was 5.4 years. The primary endpoint was the time to the first occurrence of a composite 3-component Major Adverse Cardiovascular Events (MACE) outcome, which included CV death, non-fatal myocardial infarction (MI), and non-fatal stroke. Patients eligible to enter the trial were 50 years of age or older who had type 2 diabetes mellitus, had an HbA1c value ≤9.5% with no lower limit at screening, and had either established CV disease, or did not have established CV disease but had multiple CV risk factors. Patients who were confirmed to have established CV disease (31.5% of randomized patients) had a history of at least one of the following: MI (16.2%); myocardial ischemia by a stress test or with cardiac imaging (9.3%); ischemic stroke (5.3%); coronary, carotid, or peripheral artery revascularization (18.0%); unstable angina (5.9%); or hospitalization for unstable angina with at least one of the following: ECG changes, myocardial ischemia on imaging, or a need for percutaneous coronary intervention (12.0%). Patients confirmed to be without established CV disease, but with multiple CV risk factors, comprised 62.8% of the randomized trial population. At baseline, demographic and disease characteristics were balanced between treatment groups. Patients had a mean age of 66 years; 46% were female; race: White, Black, and Asian were 76%, 7%, and 4%, respectively. The median baseline HbA1c was 7.2%. The mean duration of type 2 diabetes was 10.5 years and the mean BMI was 32.3 kg/m 2 . At baseline, 50.5% of patients had mild renal impairment (eGFR ≥60 but <90 mL/min/1.73m 2 ), 21.6% had moderate renal impairment (eGFR ≥30 but <60 mL/min/1.73m 2 ), and 1.1% of patients had severe renal impairment (eGFR <30 mL/min/1.73m 2 ) out of 9713 patients whose eGFR were available. At baseline, 94.7% of patients were taking antidiabetic medication, with 10.5% of patients taking three or more antidiabetic drugs. The most common background antidiabetic drugs used at baseline were metformin (81.2%), sulfonylurea (46.0%), and insulin (23.9%). At baseline, CV disease and risk factors were managed with ACE inhibitors or angiotensin receptor blockers (81.5%), beta blockers (45.6%), calcium channel blockers (34.4%), diuretics (46.5%), statin therapy (66.1%), antithrombotic agents (58.7%), and aspirin (51.7%). During the trial, investigators were to modify anti-diabetic and cardiovascular medications to achieve local standard of care treatment targets with respect to blood glucose, lipids, and blood pressure, and manage patients recovering from an acute coronary syndrome or stroke event per local treatment guidelines. For the primary analysis, a Cox proportional hazards model was used to test for superiority. Type I error was controlled across multiple tests. TRULICITY significantly reduced the risk of first occurrence of primary composite endpoint of CV death, non-fatal MI, or non-fatal stroke (HR: 0.88, 95% CI 0.79, 0.99). Refer to Figure 6 and Table 14 . Vital status was available for 99.7% of patients in the trial. A total of 1128 deaths were recorded during the REWIND trial. A majority of the deaths in the trial were adjudicated as CV deaths, and non-CV deaths were comparable between the treatment groups (4.4% in patients treated with TRULICITY and 5.0% in patients treated with placebo). There were 536 all-cause deaths (10.8%) in the dulaglutide group compared to 592 deaths (12.0%) in the placebo group. Number of patients at risk Placebo 4952 4791 4625 4437 4275 3575 742 Dulaglutide 4949 4815 4670 4521 4369 3686 741 Figure 6. KAPLAN MEIER CURVE: Time to First Occurrence of MACE in the REWIND Trial Table 14: Treatment Effect for MACE and the Individual Components in the REWIND Trial, Median Trial Observation Time of 5.4 years in Adult Patients with Type 2 Diabetes Mellitus a a All randomized patients. b Cox-proportional hazards model with treatment as a factor. Type I error was controlled for the primary and secondary endpoints. c p=0.026 for superiority (2-sided). d Number and percentage of patients with events. e Results for components of MACE, fatal and non-fatal stroke, and fatal and non-fatal MI are listed descriptively for supportive purposes. No statistical significance should be inferred since these CIs are not adjusted for multiplicity. Time to First Occurrence of: TRULICITY N=4949 Placebo N=4952 Hazard Ratio (95% CI) b Composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular death (MACE) d 594 (12.0%) 663 (13.4%) 0.88 (0.79, 0.99) c Cardiovascular death d,e 317 (6.4%) 346 (7.0%) 0.91 (0.78, 1.06) Non-fatal myocardial infarction d,e 205 (4.1%) 212 (4.3%) 0.96 (0.79, 1.16) Non-fatal stroke d,e 135 (2.7%) 175 (3.5%) 0.76 (0.61, 0.95) Fatal or non-fatal myocardial infarction d,e 223 (4.5%) 231 (4.7%) 0.96 (0.79, 1.15) Fatal or non-fatal stroke d,e 158 (3.2%) 205 (4.1%) 0.76 (0.62, 0.94) Figure 6 14.6 Glycemic Control Trial in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus In this 26-week randomized, double-blind, placebo-controlled, parallel-arm, multicenter trial with an open-label extension for an additional 26 weeks,154 pediatric patients 10 years of age and older with type 2 diabetes mellitus, who had inadequate glycemic control despite diet and exercise, were randomized to subcutaneous TRULICITY once weekly (0.75 mg and 1.5 mg) or subcutaneous placebo once weekly in combination with or without metformin and/or basal insulin treatment (NCT02963766). Overall, in this trial demographic and baseline disease characteristics were comparable across the treatment groups. At baseline, 71% of patients were female, and the mean age was 14.5 years (ranging from 10 to 17 years). Overall, 55% were White, 15% were Black or African American, 12% were Asian, 10% were American Indian or Alaska Native, 5% were other races, and 3% had unknown race. Additionally, 55% were Hispanic or Latino, 42% were not Hispanic or Latino, and 3% had unknown ethnicity. At baseline, the mean duration of type 2 diabetes mellitus was 2 years, mean HbA1c was 8.1%, mean weight was 90.5 kg and mean BMI was 34.1 kg/m 2 . In this trial, once weekly TRULICITY (0.75 mg and 1.5 mg, pooled) (with or without metformin and/or basal insulin) was superior to placebo (p<0.001) in the change from baseline at Week 26 in HbA1c in pediatric patients 10 years of age and older with type 2 diabetes mellitus (see Table 15 ). Table 15: Glycemic Results at Week 26 in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus with Inadequate Glycemic Control Despite Diet and Exercise (With or Without Metformin and/or Basal Insulin) Abbreviations: HbA1c = hemoglobin A1c. a Combined results for TRULICITY 0.75 mg and 1.5 mg. The comparison of the two dosages together and individually with placebo was prespecified with overall type I error controlled. b The change from baseline and difference from placebo were analyzed using analysis of covariance with effects for treatment, the baseline value as a covariate, and stratification factors which were HbA1c at screening (< 8% vs >= 8%), insulin use at baseline (yes/no), metformin use at baseline (yes/no). c For HbA1c and Fasting Blood Glucose, multiple imputation was performed for missing data guided by washout method. At Week 26 primary efficacy (HbA1c) was missing for 8%, 6%, and 10% of patients on placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg respectively. d For percentage of patients HbA1c < 7%, missing data was imputed as not achieving the target. Placebo TRULICITY 0.75 mg once weekly TRULICITY 1.5 mg once weekly TRULICITY once weekly Pooled a Intent-to-Treat Population (N) 51 51 52 103 HbA1c (%) (Mean) c Baseline Change from baseline at Week 26 b Difference from placebo (95% CI) b 8.1 0.6 - 7.9 -0.6 -1.2 (-1.8, -0.6) 8.2 -0.9 -1.5 (-2.1, -0.9) 8.0 -0.8 -1.4 (-1.9, -0.8) Percentage of Patients with HbA1c <7.0% at Week 26 d 14% 55% 48% 52% Fasting Blood Glucose (mg/dL) (Mean) c Baseline Change from baseline at Week 26 b Difference from placebo (95% CI) b 159 17.1 - 149 -12.8 -29.9 (-50.7, -9.1) 163 -24.9 -42.0 (-63.0, -20.9) 156 -18.9 -35.9 (-54.2, -17.6)

Other label records (6)

These may cover different packages or labelers. Older excerpts without full document identity are source links only.

  • TRULICITY (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Jul 3, 2025

  • Trulicity (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Dec 12, 2023

  • Trulicity (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Dec 9, 2023

  • TRULICITY (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Aug 5, 2023

  • TRULICITY (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective May 3, 2023

  • TRULICITY (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective May 3, 2023

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.
Tolerability

Side effects reported in the trial

Reported adverse events and treatment discontinuation from the cited trial. These figures do not predict an individual response.

Discontinued for side effects

8.5% (pmc.ncbi.nlm.nih.gov/articles/PMC7896253) (8.5% vs 6.0% on the 1.5 mg comparator (no placebo arm) · AWARD-11 (4.5 mg, type 2 diabetes))

Reported as 8.5% vs 6.0% on the 1.5 mg comparator (no placebo arm). The share of trial participants who stopped treatment because of adverse events. This does not measure all side effects or all reasons for stopping.

Had nausea

17.3% (pmc.ncbi.nlm.nih.gov/articles/PMC7896253) (Nausea in the drug arm · AWARD-11 (4.5 mg, type 2 diabetes))

The share of participants who reported nausea in this trial. Severity and duration are not captured by this percentage.

Nausea (17%), diarrhea (12%), and vomiting (10%) were the most common events at 4.5 mg, predominantly mild-to-moderate; GI burden is lower than the obesity-dose agents.

From AWARD-11 (4.5 mg, type 2 diabetes) (a type 2 diabetes trial with no placebo arm (the contrast is vs dulaglutide 1.5 mg), so it is not one-to-one with the obesity-trial figures). Tolerability figures come from each drug's own trial (different doses, durations, and populations), so compare them as a guide, not a head-to-head. Source (pmc.ncbi.nlm.nih.gov).

Safety signals

Beyond the US label

Regulators' safety notices beside the US label, each cited and dated. Where it matters, each says whether the label itself mentions it yet.

Before surgery: risk of pulmonary aspiration

In November 2024 the FDA added a class-wide warning to every GLP-1 label. Because these drugs slow stomach emptying, food can remain in the stomach before a procedure and be inhaled into the lungs (aspiration) during general anesthesia or deep sedation, even after normal fasting. Tell your care team you take a GLP-1 well before any planned surgery or sedation.

FDA (class-wide label update) (secure.medicalletter.org) · as of Nov 5, 2024

Eyes: FDA requires a warning about sudden vision loss (NAION)

On November 9, 2026 the FDA said it is "requiring application holders for all GLP-1 RA medications to add information to the Warnings and Precautions section of labeling about the potential increased risk of NAION" (non-arteritic anterior ischemic optic neuropathy), which it describes as "a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss." Its analysis of 126 randomized trials found 6.4 NAION cases per 100,000 person-years on a GLP-1, against 3.8 on placebo or another glucose-lowering medicine. Its list names every GLP-1 sold in the US, from Ozempic, Wegovy, Mounjaro and Zepbound to Foundayo. FDA's advice: "Patients should contact their health care professional right away if they have any of these symptoms." None of the current US labels of Byetta, Wegovy, Rybelsus/Ozempic tablets, Trulicity, Saxenda, Victoza, Mounjaro, Zepbound, Ozempic and Foundayo mentions NAION; every new revision is searched in full within a day of its publication.

FDA Drug Safety Communication, November 9, 2026 (fda.gov) · as of Nov 9, 2026

Evidence

Clinical trials

97 of 145 registered studies indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.

  • Primary outcome: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)

    Count of participants · Participants · From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)

    Analysis population: All randomized participants.

    Placebo
    663 Participants (clinicaltrials.gov/study/NCT01394952)

    Overall outcome: 4952 Participants (clinicaltrials.gov/study/NCT01394952) analyzed

    Dulaglutide
    594 Participants (clinicaltrials.gov/study/NCT01394952)

    Overall outcome: 4949 Participants (clinicaltrials.gov/study/NCT01394952) analyzed

    Outcome definition & treatment groups

    The time from randomization to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite endpoint) was evaluated using time-to-event analysis. The primary analysis model was a Cox proportional hazards regression model for the time to the first occurrence of a primary endpoint event, with treatment as a fixed effect using the intent-to-treat population. The number of participants who experienced a primary cardiovascular (CV) endpoint event is presented.

    Placebo: Placebo was administered once weekly, subcutaneously

    Dulaglutide: 1.5 mg Dulaglutide was administered once weekly, subcutaneously

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change in Hemoglobin A1c (HbA1c) From Baseline

    Selected primary outcome

    Results · Oct 29, 2026 UTC

    Change in Hemoglobin A1c (HbA1c) From Baseline

    Least-squares mean · Percentage of HbA1c · Baseline, Week 36

    Analysis population: All participants who received at least one dose of study drug and had a baseline and at least 1 post-baseline HbA1c value, excluding data post treatment discontinuation and/or initiation of new antihyperglycemic medications.

    Dulaglutide 1.5 mg
    -1.53 Percentage of HbA1c (clinicaltrials.gov/study/NCT03495102)

    Standard Error: 0.04 (clinicaltrials.gov)

    Overall outcome: 523 Participants (clinicaltrials.gov/study/NCT03495102) analyzed

    Dulaglutide 3 mg
    -1.71 Percentage of HbA1c (clinicaltrials.gov/study/NCT03495102)

    Standard Error: 0.04 (clinicaltrials.gov)

    Overall outcome: 521 Participants (clinicaltrials.gov/study/NCT03495102) analyzed

    Dulaglutide 4.5 mg
    -1.87 Percentage of HbA1c (clinicaltrials.gov/study/NCT03495102)

    Standard Error: 0.04 (clinicaltrials.gov)

    Overall outcome: 526 Participants (clinicaltrials.gov/study/NCT03495102) analyzed

    Outcome definition & treatment groups

    HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The Least Squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included the independent variables:Baseline + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Dulaglutide 1.5 mg: Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.

    Dulaglutide 3 mg: Dulaglutide 3 mg administered SC once a week.

    Dulaglutide 4.5 mg: Dulaglutide 4.5 mg administered SC once a week.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Glycosylated Hemoglobin (HbA1c) Change From Baseline

    Selected primary outcome

    Results · Nov 4, 2026 UTC

    Glycosylated Hemoglobin (HbA1c) Change From Baseline

    Least-squares mean · percentage of HbA1c · Baseline, 52 weeks

    Analysis population: All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms who had evaluable HbA1c data. Last observation carried forward was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.

    1.5 mg LY2189265
    -1.10 percentage of HbA1c (clinicaltrials.gov/study/NCT00734474)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 301 Participants (clinicaltrials.gov/study/NCT00734474) analyzed

    0.75 mg LY2189265
    -0.87 percentage of HbA1c (clinicaltrials.gov/study/NCT00734474)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 297 Participants (clinicaltrials.gov/study/NCT00734474) analyzed

    Sitagliptin
    -0.39 percentage of HbA1c (clinicaltrials.gov/study/NCT00734474)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 311 Participants (clinicaltrials.gov/study/NCT00734474) analyzed

    Outcome definition & treatment groups

    Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.

    1.5 mg LY2189265: LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks Placebo: tablet, administered orally, once daily for 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks

    0.75 mg LY2189265: LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks Placebo: tablet, administered orally, once daily for 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks

    Sitagliptin: Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Has results
    Primary outcome: Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

    Selected primary outcome

    Results · Nov 6, 2026 UTC

    Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least-squares mean · percentage of glycosylated hemoglobin · Baseline, 26 weeks

    Analysis population: Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.

    1.5 mg LY2189265
    -1.51 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01064687)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 271 Participants (clinicaltrials.gov/study/NCT01064687) analyzed

    0.75 mg LY2189265
    -1.30 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01064687)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 269 Participants (clinicaltrials.gov/study/NCT01064687) analyzed

    Exenatide
    -0.99 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01064687)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 266 Participants (clinicaltrials.gov/study/NCT01064687) analyzed

    Placebo
    -0.46 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01064687)

    Standard Error: 0.08 (clinicaltrials.gov)

    Overall outcome: 119 Participants (clinicaltrials.gov/study/NCT01064687) analyzed

    Outcome definition & treatment groups

    Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.

    1.5 mg LY2189265: LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks Pioglitazone: at least 30 mg/day, oral, for 52 weeks

    0.75 mg LY2189265: LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks Pioglitazone: at least 30 mg/day, oral, for 52 weeks

    Exenatide: Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks Pioglitazone: at least 30 mg/day, oral, for 52 weeks

    Placebo: Placebo: subcutaneous (SC), once weekly for 26 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks Pioglitazone: at least 30 mg/day, oral, for 26 weeks

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline to Week 56 in HbA1c

    Selected primary outcome

    Results · Nov 6, 2026 UTC

    Change From Baseline to Week 56 in HbA1c

    Least-squares mean · percentage of HbA1c · Baseline to Week 56

    Analysis population: Analysis was performed on modified intent-to-treat (mITT) population which included participants who completed study treatment; or who discontinued study treatment and completed/discontinued study before early termination; or who discontinued treatment before early termination and discontinued study due to early termination; or who discontinued treatment due to early termination within 30 days of target Week 56 visit.

    Efpeglenatide 4 mg
    -1.12 percentage of HbA1c (clinicaltrials.gov/study/NCT03684642)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 257 Participants (clinicaltrials.gov/study/NCT03684642) analyzed

    Efpeglenatide 6 mg
    -1.17 percentage of HbA1c (clinicaltrials.gov/study/NCT03684642)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 254 Participants (clinicaltrials.gov/study/NCT03684642) analyzed

    Dulaglutide 1.5 mg
    -1.09 percentage of HbA1c (clinicaltrials.gov/study/NCT03684642)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 250 Participants (clinicaltrials.gov/study/NCT03684642) analyzed

    Outcome definition & treatment groups

    Adjusted Least square (LS) means and Standard errors (SE) were obtained from analysis of covariance (ANCOVA) model to account for missing data. Missing values were imputed by baseline observation carried forward (BOCF)-like multiple imputation method.

    Efpeglenatide 4 mg: Participants received Efpeglenatide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 4 mg once weekly for the treatment duration.

    Efpeglenatide 6 mg: Participants received Efpeglenatide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 6 mg once weekly for the treatment duration.

    Dulaglutide 1.5 mg: Participants received Dulaglutide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 0.75 mg once weekly and increased after 2 weeks to 1.5 mg once weekly for the treatment duration.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Has results
    Primary outcome: Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)

    Selected primary outcome

    Results · Oct 30, 2026 UTC

    Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least-squares mean · percentage of glycosylated hemoglobin · Baseline, 26 weeks

    Analysis population: Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.

    1.5 mg LY2189265
    -1.64 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01191268)

    Standard Error: 0.07 (clinicaltrials.gov)

    Overall outcome: 273 Participants (clinicaltrials.gov/study/NCT01191268) analyzed

    0.75 mg LY2189265
    -1.59 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01191268)

    Standard Error: 0.07 (clinicaltrials.gov)

    Overall outcome: 275 Participants (clinicaltrials.gov/study/NCT01191268) analyzed

    Insulin Glargine
    -1.41 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01191268)

    Standard Error: 0.07 (clinicaltrials.gov)

    Overall outcome: 276 Participants (clinicaltrials.gov/study/NCT01191268) analyzed

    Outcome definition & treatment groups

    Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.

    1.5 mg LY2189265: LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks

    0.75 mg LY2189265: LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks

    Insulin Glargine: Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Has results
    Primary outcome: Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

    Selected primary outcome

    Results · Nov 6, 2026 UTC

    Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least-squares mean · percentage of glycosylated hemoglobin · Baseline, 52 weeks

    Analysis population: Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.

    LY2189265 1.5 mg
    -1.08 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01075282)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 263 Participants (clinicaltrials.gov/study/NCT01075282) analyzed

    LY2189265 0.75 mg
    -0.76 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01075282)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 267 Participants (clinicaltrials.gov/study/NCT01075282) analyzed

    Insulin Glargine
    -0.63 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01075282)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 259 Participants (clinicaltrials.gov/study/NCT01075282) analyzed

    Outcome definition & treatment groups

    Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.

    LY2189265 1.5 mg: LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks Glimepiride: at least 4 mg/day, oral, for 78 weeks

    LY2189265 0.75 mg: LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks Glimepiride: at least 4 mg/day, oral, for 78 weeks

    Insulin Glargine: Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 78 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks Glimepiride: at least 4 mg/day, oral, for 78 weeks

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Has results
    Primary outcome: Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)

    Selected primary outcome

    Results · Nov 6, 2026 UTC

    Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least-squares mean · percentage of glycosylated hemoglobin · Baseline, 26 weeks

    Analysis population: Participants who received at least one dose of LY2189265 or Metformin with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.

    1.5 mg LY2189265
    -0.78 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01126580)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 265 Participants (clinicaltrials.gov/study/NCT01126580) analyzed

    0.75 mg LY2189265
    -0.71 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01126580)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 265 Participants (clinicaltrials.gov/study/NCT01126580) analyzed

    Metformin
    -0.56 percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT01126580)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 265 Participants (clinicaltrials.gov/study/NCT01126580) analyzed

    Outcome definition & treatment groups

    Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \[OAM\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.

    1.5 mg LY2189265: LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks Placebo: orally, twice daily for 52 weeks

    0.75 mg LY2189265: LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks Placebo: orally, twice daily for 52 weeks

    Metformin: Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks Placebo: subcutaneously (SC), once weekly for 52 weeks

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks

    Selected primary outcome

    Results · Nov 3, 2026 UTC

    Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks

    Least-squares mean · percentage of HbA1c · Baseline, 26 Weeks

    Analysis population: Participants who were randomized, received at least one dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.

    1.5 mg Dulaglutide
    -1.73 percentage of HbA1c (clinicaltrials.gov/study/NCT01648582)

    Standard Error: 0.067 (clinicaltrials.gov)

    Overall outcome: 253 Participants (clinicaltrials.gov/study/NCT01648582) analyzed

    0.75 mg Dulaglutide
    -1.33 percentage of HbA1c (clinicaltrials.gov/study/NCT01648582)

    Standard Error: 0.067 (clinicaltrials.gov)

    Overall outcome: 252 Participants (clinicaltrials.gov/study/NCT01648582) analyzed

    Insulin Glargine
    -1.16 percentage of HbA1c (clinicaltrials.gov/study/NCT01648582)

    Standard Error: 0.067 (clinicaltrials.gov)

    Overall outcome: 250 Participants (clinicaltrials.gov/study/NCT01648582) analyzed

    Outcome definition & treatment groups

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means of change from baseline in HbA1c were calculated using a mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, oral antihyperglycemic medication (OAM) , visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.

    1.5 mg Dulaglutide: 1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.

    0.75 mg Dulaglutide: 0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.

    Insulin Glargine: Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in HbA1c at 26 Weeks

    Selected primary outcome

    Results · Nov 4, 2026 UTC

    Change From Baseline in HbA1c at 26 Weeks

    Least-squares mean · percentage of HbA1c · Baseline, 26 Weeks

    Analysis population: Participants who had been randomized, received at least one dose of study drug, had a baseline HbA1c measurement, and had at least one post-baseline HbA1c measurement.

    1.5 mg Dulaglutide
    -1.48 percentage of HbA1c (clinicaltrials.gov/study/NCT01644500)

    Standard Error: 0.069 (clinicaltrials.gov)

    Overall outcome: 239 Participants (clinicaltrials.gov/study/NCT01644500) analyzed

    0.75 mg Dulaglutide
    -1.22 percentage of HbA1c (clinicaltrials.gov/study/NCT01644500)

    Standard Error: 0.069 (clinicaltrials.gov)

    Overall outcome: 239 Participants (clinicaltrials.gov/study/NCT01644500) analyzed

    Glimepiride
    -0.92 percentage of HbA1c (clinicaltrials.gov/study/NCT01644500)

    Standard Error: 0.069 (clinicaltrials.gov)

    Overall outcome: 242 Participants (clinicaltrials.gov/study/NCT01644500) analyzed

    Outcome definition & treatment groups

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline HbA1c as covariate; and participant as a random effect.

    1.5 mg Dulaglutide: 1.5 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.

    0.75 mg Dulaglutide: 0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.

    Glimepiride: 1 to 3 mg/day glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26

    Selected primary outcome

    Results · Nov 6, 2026 UTC

    Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26

    Least-squares mean · Percentage of HbA1c · Baseline, Week 26

    Analysis population: All randomly assigned participants, excluding the GCP compliance investigative site, who were exposed to at least 1 dose of study intervention and had at least one post baseline value for this analysis.

    Dulaglutide 1.5 mg
    -1.53 Percentage of HbA1c (clinicaltrials.gov/study/NCT04809220)

    Standard Error: 0.043 (clinicaltrials.gov)

    Overall outcome: 383 Participants (clinicaltrials.gov/study/NCT04809220) analyzed

    Dulaglutide 0.75 mg
    -1.25 Percentage of HbA1c (clinicaltrials.gov/study/NCT04809220)

    Standard Error: 0.060 (clinicaltrials.gov)

    Overall outcome: 193 Participants (clinicaltrials.gov/study/NCT04809220) analyzed

    Outcome definition & treatment groups

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Pre-study oral antihyperglycemic medication (OAM) Group 1 + Treatment + Time + Treatment × Time as variables.

    Dulaglutide 1.5 mg: Participants received 1.5 mg of dulaglutide given weekly SC during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 OAM. Participants on DPP-4i discontinued DPP-4i at randomization and was regarded as monotherapy of dulaglutide, other OAMs continued at same dose during study period and were regarded as combination therapy with dulaglutide.

    Dulaglutide 0.75 mg: Participants received 0.75 mg of dulaglutide given weekly SC during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 OAM. Participants on DPP-4i discontinued DPP-4i at randomization and was regarded as monotherapy of dulaglutide, other OAMs continued at same dose during study period and were regarded as combination therapy with dulaglutide

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Hemoglobin A1c (HbA1c)

    Selected primary outcome

    Results · Nov 4, 2026 UTC

    Change From Baseline in Hemoglobin A1c (HbA1c)

    Least-squares mean · percentage of HbA1c · Baseline, 26 Weeks

    Analysis population: All randomized participants who received at least one dose of study drug and had evaluable baseline and post-baseline HbA1c data. Only measurements prior to rescue or study drug discontinuation were used.

    Insulin Glargine
    -1.13 percentage of HbA1c (clinicaltrials.gov/study/NCT01621178)

    Standard Error: 0.12 (clinicaltrials.gov)

    Overall outcome: 175 Participants (clinicaltrials.gov/study/NCT01621178) analyzed

    Dulaglutide 0.75 mg
    -1.12 percentage of HbA1c (clinicaltrials.gov/study/NCT01621178)

    Standard Error: 0.12 (clinicaltrials.gov)

    Overall outcome: 149 Participants (clinicaltrials.gov/study/NCT01621178) analyzed

    Dulaglutide 1.5 mg
    -1.19 percentage of HbA1c (clinicaltrials.gov/study/NCT01621178)

    Standard Error: 0.13 (clinicaltrials.gov)

    Overall outcome: 138 Participants (clinicaltrials.gov/study/NCT01621178) analyzed

    Outcome definition & treatment groups

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means in HbA1c were calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, macroalbuminuria (MA) region, Baseline CKD Severity, week, treatment\*week, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.

    Insulin Glargine: Insulin glargine was administered subcutaneous (SC) at bedtime per a modified forced-titration treat-to-target algorithm. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.

    Dulaglutide 0.75 mg: Dulaglutide 0.75 mg was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.

    Dulaglutide 1.5 mg: Dulaglutide 1.5 mg was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

Source: ClinicalTrials.gov API v2 (clinicaltrials.gov/search) · as of Nov 17, 2026

All trials on ClinicalTrials.gov (clinicaltrials.gov)
FDA enforcement archive

Recall records

Enforcement records describe specific recalled products and lots. They do not establish the recall status of every product containing the ingredient. openFDA does not maintain current recall status after classification; read the FDA record and any manufacturer notice for details.

3 indexed product records, ordered by FDA report date. One recall event may include several products.

D-0883-2022

Class IIFDA report: May 25, 2022

Recalling firm: Cardinal Health Inc.

Trulicity (dulaglutide) injection, 1.5 mg/0.5mL once weekly, 4 Single-Dose Pens, Rx only, Eli Lilly and Company, Indianapolis, IN 46285, NDC 00002-1434-80

Reason for recall

TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions due to inclement weather.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0884-2022

Class IIFDA report: May 25, 2022

Recalling firm: Cardinal Health Inc.

Trulicity (dulaglutide) injection, 0.75 mg/0.5mL once weekly, 4 Single-Dose Pens, Rx only, Eli Lilly and Company, Indianapolis, IN 46285, NDC 0002-1433-80

Reason for recall

TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0773-2021

Class IIFDA report: Sep 1, 2021

Recalling firm: Eli Lilly & Company

Trulicity (dulaglutide), 0.75 mg/0.5 mL, 4 Single-Dose Pens per box, Rx only, Eli Lilly and Company, Indianapolis, IN 46285, NDC 0002-1433-80

Reason for recall

Labeling: Label error on declared strength - autoinjector devices labeled as 0.75 mg / 0.5 mL actually contain 1.5 mg / 0.5 mL of product.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

Browse the FDA enforcement archive (accessdata.fda.gov) · Source coverage & limitations (open.fda.gov)

Related

Related GLP-1s to compare

Updated automatically

What changed for Dulaglutide

  • PriceSingleCare: Trulicity pens (SingleCare coupon) now ranked per 30 days at about $914: ~$853 per 4 pens buys 28 days (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • PriceGoodRx: Trulicity (brand, all doses) now ~$992/mo (was ~$952/mo) (read on goodrx.com)
  • TrialNew Dulaglutide study registered: Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes (clinicaltrials.gov/study/NCT07834398)
  • FDA labelFDA label updated: Trulicity (Eli Lilly and Company), effective 2026-06-16 (api.fda.gov/drug/label.json)
  • FDAFDA approved a labeling supplement for Trulicity (accessdata.fda.gov/scripts/cder/daf/index.cfm)
  • FDAFDA approved a labeling supplement for Trulicity (accessdata.fda.gov/scripts/cder/daf/index.cfm)

Written from each source's own record as it changes. Every change on GLPcompare

ClinicalTrials.gov

What Dulaglutide is studied for

Registered trials of this medicine by condition. A trial shows a question being asked, not that the answer is yes.

From PubMed

Latest Dulaglutide trials and reviews

  • Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials (pubmed.ncbi.nlm.nih.gov/42706739)

    Meta-analysis · Endocrinol Diabetes Metab · Sep 1, 2026 · Hageen AW et al.

  • Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA) (pubmed.ncbi.nlm.nih.gov/42618811)

    Randomized trial · Diabetologia · Aug 19, 2026 · Adly AAM et al.

  • Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials (pubmed.ncbi.nlm.nih.gov/42897592)

    Meta-analysis · Diabetol Metab Syndr · Jul 24, 2026 · Hassan M et al.

  • Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial (pubmed.ncbi.nlm.nih.gov/42321509)

    Randomized trial · Neurol Ther · Jun 20, 2026 · Šiarnik P et al.

  • Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses (pubmed.ncbi.nlm.nih.gov/42388875)

    Randomized trial · Front Endocrinol (Lausanne) · Jun 17, 2026 · Jun JE et al.

  • Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial (pubmed.ncbi.nlm.nih.gov/42229460)

    Randomized trial · Diabetes Obes Metab · Jun 2, 2026 · Heise T et al.

  • Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/41903177)

    Randomized trial · JAMA Cardiol · Jun 1, 2026 · Nissen SE et al. · cited by 6

  • A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial (pubmed.ncbi.nlm.nih.gov/42114520)

    Randomized trial · Lancet Diabetes Endocrinol · May 11, 2026 · Zoungas S et al. · cited by 8

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

Common questions about Dulaglutide

What is the brand name of dulaglutide?
Dulaglutide is sold in the US as Trulicity. A compounded version has no brand name and is not FDA-approved.
Is Dulaglutide in shortage?
No matching shortage record was returned in the latest complete FDA check. Last complete check: Nov 17, 2026. Confirm local stock with your pharmacy. Source (accessdata.fda.gov)
Is there a generic dulaglutide?
No. Trulicity is licensed as a biologic, so a copy would be a biosimilar, and FDA's record holds no application for one. Source
How much does Dulaglutide cost per month?
Among the sourced FDA-approved offers in our catalog, a tracked starting quote is from $389/28 days for Trulicity single-dose pens via LillyDirect (Eli Lilly). ≈ $416.79 per 30 days at this quoted rate. self-pay, four weekly pens; published starting rate at each dose The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. LillyDirect defines a month's supply as four single-dose pens, one a week, so a fill covers 28 days. 28-day supply The quote at the cited trial dose is from $389/28 days for Trulicity single-dose pens at 4.5 mg via LillyDirect (Eli Lilly). Published price at 4.5 mg The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. LillyDirect defines a month's supply as four single-dose pens, one a week, so a fill covers 28 days. The same starting rate is published for 0.75, 1.5, 3 and 4.5 mg. Taxes and additional fees may apply. 28-day supply Starting and trial-dose quotes may cover different products. These are self-pay offers, not insurance estimates or a guarantee of eligibility. Source (lilly.com)
How much weight can you lose on Dulaglutide?
In its pivotal trial (AWARD-11), Dulaglutide at 4.5 mg weekly (Trulicity) showed a mean body-weight change of -4.6 kg (~4.8% of the 95.4 kg baseline) at 36 wks. This is a trial average; individual results vary. Source (diabetesjournals.org)
What is Dulaglutide approved for?
Approved uses across Dulaglutide products include type 2 diabetes and cardiovascular risk reduction. Indications differ by brand and formulation; this does not mean every product is approved for every use. See the product-specific prescribing information above.